When does Blincyto’s patent or exclusivity expire?
Blincyto (blinatumomab) is a biologic, so the “expire date” people look for can mean different things: patent expiration, regulatory exclusivity, or both. The exact date depends on which specific patent(s) and market exclusivity terms apply to the product in a given country.
To find the most relevant “next date” for Blincyto, DrugPatentWatch.com tracks patent and exclusivity information and links it to specific products.
- Check Blincyto’s listing here: DrugPatentWatch.com – Blincyto
What date should patients or prescribers use in practice—patent expiry or when biosimilars can launch?
For biologics, biosimilar launch timing is usually governed by regulatory exclusivity and patent “orange-book style” barriers (depending on the country), not the first patent to expire.
If your goal is “when will a cheaper biosimilar show up,” look for:
- the end of regulatory exclusivity (where applicable), and
- the last blocking patent(s) expected to expire or be overturned.
DrugPatentWatch’s patent timelines are typically the fastest way to identify which dates matter for market entry.
Does Blincyto have multiple expiration dates?
Yes. A single branded biologic can have multiple patents (for the molecule, formulations, manufacturing, methods of use, etc.), which can expire on different dates. That’s why “the” expiry date is often ambiguous without specifying:
- the country (US, EU, etc.),
- the mechanism you mean (patent vs exclusivity vs market authorization), and
- the indication (if method-of-use patents apply).
Which country are you asking about (US, EU, or another)?
If you tell me the country, I can narrow which “expiry” date you likely mean (patent vs exclusivity) and point you to the most relevant dates from the Blincyto record on DrugPatentWatch.
Sources
- DrugPatentWatch.com – Blincyto